New Haven’s Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its proprietary tumor-targeting platform, on Monday announced that Arthur DeCillis, MD has joined the company as acting chief medical officer. He will be responsible for the development of the first-in-human study of Cybrexa’s lead program, CBX-12 (alphalex, generically known as exatecan), and early- and late-stage clinical programs for the Cybrexa portfolio.
Before forming his own medical consulting practice, DeCillis was CMO for Eleven Biotherapeutics (now Sesen Bio Inc.), a late-stage clinical company developing next-generation antibody-drug conjugate (ADC) therapies. Previously he was vice president of clinical research and then vice president of medical affairs at Exelixis Inc., an oncology-focused biotechnology company. He also previously served as executive director of oncology development for Novartis and group director of Bristol-Myers Squibb.
DeCillis earned his MD from the University of Rochester and completed an internal medicine residency at Medical College of Virginia followed by a fellowship at the University of Pittsburgh.
***
New Haven biopharma Rallybio LLC has engaged Michael Greco, JD to head the firm’s legal function. Greco will have responsibility for Rallybio’s legal, intellectual property, compliance and governance activities. Greco previously was first general counsel of SpringWorks Therapeutics, and before that senior vice president of law and corporate secretary of Alexion Pharmaceuticals. Greco earned his JD from Suffolk University Law School, and a BS from the U.S. Military Academy at West Point.
